Bevacizumab: the first agent to remarkably improve survival in recurrent cervical cancer

Bevacizumab significantly improved overall survival when added to chemotherapy in women with recurrent or metastatic cervical cancer, according to a planned interim analysis of the Gynecologic Oncology Group 240 study presented at the Plenary session of 2013 Annual Meeting of the American Society for Clinical Oncology. This is the first time that a targeted agent has demonstrated such an improvement in gynecologic cancers. Read more here.